The Food and Drug Administration advisory committee is now scheduled to meet Feb. 26 for an all-day meeting to discuss Johnson & Johnson’s JNJ,
Candidate of COVID-19 vaccine. This is the next step in the regulatory process after J&J said Thursday that it has submitted an application for its experimental vaccine to the FDA. Members of the Vaccines and Related Biological Products Advisory Committee will then discuss whether to vote on whether the benefits of the one – dose vaccine outweigh the risks. The FDA then takes into account the committee’s recommendation while deciding whether to approve a J&J bullet. The advisory committee also held meetings to discuss the COVID-19 vaccines developed by BioNTech SE BNTX,
/ Pfizer Inc. PFE,
and Moderna Inc. MRNA,
Both vaccines were recommended by the committee, and emergency approvals were issued by the FDA within days of those meetings. J&J stock has gained 5.2% over the past 12 months, and the S&P 500 SPX more broadly,
it is up 17.4%.